Genetic variants and family history predict prostate cancer similar to prostate-specific antigen

S. Lilly Zheng, Jielin Sun, Fredrik Wiklund, Zhengrong Gao, Pär Stattin, Lina D. Purcell, Hans Olov Adami, Fang Chi Hsu, Yi Zhu, Jan Adolfsson, Jan Erik Johansson, Aubrey R. Turner, Tamara S. Adams, Wennuan Liu, David Duggan, John D. Carpten, Bao Li Chang, William B. Isaacs, Jianfeng Xu, Henrik Grönberg

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Although prostate-specific antigen (PSA) is the best biomarker for predicting prostate cancer, its predictive performance needs to be improved. Results from the Prostate Cancer Prevention Trial revealed the overall performance measured by the areas under curve of the receiver operating characteristic at 0.68. The goal of the present study is to assess the ability of genetic variants as a PSA-independent method to predict prostate cancer risk. Experimental Design: We systematically evaluated all prostate cancer risk variants that were identified from genome-wide association studies during the past year in a large population-based prostate cancer case-control study population in Sweden, including 2,893 prostate cancer patients and 1,781 men without prostate cancer. Results: Twelve single nucleotide polymorphisms were independently associated with prostate cancer risk in this Swedish study population. Using a cutoff of any 11 risk alleles or family history, the sensitivity and specificity for predicting prostate cancer were 0.25 and 0.86, respectively. The overall predictive performance of prostate cancer using genetic variants, family history, and age, measured by areas under curve was 0.65 (95% confidence interval, 0.63-0.66), significantly improved over that of family history and age (0.61%; 95% confidence interval, 0.59-0.62; P = 2.3 × 10 -10). Conclusion: The predictive performance for prostate cancer using genetic variants and family history is similar to that of PSA. The utility of genetic testing, alone and in combination with PSA levels, should be evaluated in large studies such as the European Randomized Study for Prostate Cancer trial and Prostate Cancer Prevention Trial.

Original languageEnglish (US)
Pages (from-to)1105-1111
Number of pages7
JournalClinical Cancer Research
Volume15
Issue number3
DOIs
StatePublished - Feb 1 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Genetic variants and family history predict prostate cancer similar to prostate-specific antigen'. Together they form a unique fingerprint.

Cite this